C reated in 1992, Human Genome Sciences remains a pioneer in the gene-based drug development business. But its travails illustrate just how long it can take to move an experimental treatment from the laboratory to the consumer market. None of the company's drugs have reached that milestone. Just 2 months ago, the company jettisoned its top candidate drug for regulatory approval, a seemingly promising treatment for painful skin sores, after the drug failed to work in a large human test (Washington Post, accessed October 29, 2003, at http://www.washingtonpost.com).
Chronic nonhealing wounds are an important medical ailment that afflict between 0.18% and 1.3% of the adult population. [1] [2] [3] [4] They account for at least $1 billion per year in health care costs in the United States and $7 billion per year worldwide. [5] [6] [7] Chronic wounds result in diminished quality of life, frequent hospitalizations and health care provider visits, and increased morbidity and mortality. 5, 8, 9 These wounds are associated with feelings of fear, social isolation, anger, depression, and resentment. 9, 10 Chronic wounds are often located on a lower extremity. Most commonly, these wounds are associated with venous disease, arterial insufficiency, or a diabetic insensate foot ulcer. 3, 7, 11 Despite momentous basic science advances in the understanding of wound repair, most patients with chronic wounds on a lower extremity still fail to heal in a reasonable period of time. 4, 6, [12] [13] [14] This should be an exciting time for clinicians treating patients with chronic wounds, but despite considerable advances in elucidating the molecular basis of wound repair, attempts at developing new therapies have been disappointing. [14] [15] [16] [17] In general, therapies based on recently uncovered mechanisms of wound repair have shown minimal to moderate improvement in the overall percentage of individuals with a healed venous leg or diabetic foot ulcer. 7, [18] [19] [20] [21] [22] [23] [24] Their effect has been dramatically less than what would have been predicted from animal studies. Other than what are basically "me-too" bandage device approvals, only 2 categories of treatments have received Food and Drug Administration (FDA) approval.
One category is the skin substitutes (also called cellbased therapy), and one of these has been approved for use in the treatment of diabetic neuropathic foot ulcers and venous leg ulcers. 19, 24, 25 The other category includes the cytokines. In this category, only recombinant human platelet derived growth factor (rhPDGF) (also called a cytokine) has been approved by the FDA for the treatment of diabetic neuropathic foot ulcer. 22, 26 However, even with the advent of these new products, success in treating diabetic neuropathic foot ulcers and venous leg ulcers is not adequate. For example, approximately 33% of diabetic neuropathic foot ulcer patients in the standard care arms of clinical trials will heal by 20 weeks of care, while approximately 43% of the individuals that receive rhPDGF will heal by 20 weeks of care. 22, 26 Treatment for patients with venous leg ulcers and a skin substitute is not much better. Within 24 weeks of care, about 63% of those treated with a skin substitute will heal, while 49% of those receiving standard care will heal. 25 In reality, both rhPDGF and skin substitutes are really adjuvants to standard care that has not dramatically changed in many years.
Many other experimental agents have been evaluated in randomized controlled trials for the treatment for venous leg ulcers, pressure ulcers, and diabetic neuropathic foot ulcers. These trials have included the use of growth factors such as PDGF, TGF-β, TGF-α, EGF, GM-CSF, IGF, aFGF, bFGF, and KGF and "culturegrown" skin. 13, 23 Two very early clinical studies have shown that bone marrow-derived cells may be effective for the treatment of chronic wounds. 27, 28 Unfortunately, as is too common in chronic wound clinical trials, many early wound care studies show an effect that is later not substantiated in larger trials.
The reason for the failure of these novel pharmaceuticals to show efficacy is not clear, and in fact many of these agents did show a trend toward superiority over standard care when evaluated in randomized clinical trials. At least in part, this lack of success at finding new agents may be related to the expense of con-ducting randomized clinical trials for chronic wounds and inadequately designed clinical trials such that the studies were not able to find differences between treatment groups that may have existed. Other potential reasons for their failure to gain statistical significance include ineffective therapy (eg, growth factors do not augment healing), ineffective delivery of the novel therapy to the tissues involved in wound repair, and poor choice of outcome measures. [29] [30] [31] [32] [33] To summarize, human chronic wound healing studies using experimental agents (eg, topically applied growth factors or skin substitutes) have not shown as dramatic an improvement in treating these chronic ailments as what would have been expected from preclinical animal studies. In general, very few new experimental treatments for chronic wounds have performed as well in the clinical setting as in the preclinical lab setting. It is time for us to design better trials by having a better understanding of how our patients respond to standard care, by having a better idea of who is most likely to benefit from a new therapy (ie, how the patient's clinical phenotype will respond to current care), and to be more creative in understanding appropriate endpoints for those with chronic wounds. Finally, we also need to be conscious of the cost of new therapies. Just because a new therapy exists does not mean that a health system will be able to justify the cost of the new therapy. This is a tall order, but we must be up to the challenge if we are to truly begin to reap the scientific benefit of the past 20 years for those with chronic wounds.
